Considering all the results above, it seemed that 6 months of PD1 antibody monotherapy might be preferred to achieve the greatest possibility of CR in CRC, which was supported by another prospective study, which demonstrated that the median time to reach a clinical complete response was 5·2 months [13, 20]. The gene discussed is PDCD1; the disease is colorectal carcinoma.